Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (06990.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 471.00

From 52W high−20.07%

Volume1.32M

Market capHKD 107.64B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 471.00

From 52W high

−20.07%

Volume

1.32M

Market cap

HKD 107.64B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

36.2

MomentumView details →

1D Return

+0.04%

YTD Return

+17.34%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

71.88%

Net Margin

−18.59%

EBITDA Margin

−17.72%

ROE (TTM)

−8.60%

ROA (TTM)

−6.99%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+36.79%

EPS CAGR 3Y

−38.33%

EBITDA YoY

—

MomentumView details →

1D Return

+0.04%

YTD Return

+17.34%

1Y Return

−9.40%

RSI (14)

36.2

vs 50D SMA

−8.37%

vs 200D SMA

+1.83%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

5.13x

Quick Ratio

4.89x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

HKD 0.24

EPS Surprise

612.46%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 1.76

Avg Surprise (4Q)

612.46%

Rev Surprise

−90.05%

Financials snapshotView financials →

Revenue (TTM)

2.25B

Net Income (TTM)

−418.48M

Op. CF (TTM)

−191.74M

Next earningsMar 29, 2027 →

Latest newsMore news →

Kelun-Biotech announced that its partner Windward Bio AG reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial for SKB378/WIN378, a TSLP-targeting monoclonal antibody for asthma, and the Phase 3 portion has been initiated.12d ago

Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.34d ago

Similar companies

ORIENT BIO Inc.002630.KS CG Invites Co., Ltd.083790.KQ iNtRON Biotechnology, Inc.048530.KQ Vaxcell-Bio Therapeutics Co., Ltd.323990.KQ MedPacto, Inc.235980.KQ Sino Biopharmaceutical Limited01177.HK Find similar companies →

Latest newsMore news →

Kelun-Biotech announced that its partner Windward Bio AG reported positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial for SKB378/WIN378, a TSLP-targeting monoclonal antibody for asthma, and the Phase 3 portion has been initiated.12d ago Kelun-Biotech reported its first-half 2026 results, with net profit of 388 million yuan, turning from a loss of 145 million yuan a year earlier.34d ago